Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for alleged misleading statements and undisclosed material changes to its glucose monitoring systems during the specified class period [1][2]. Group 1: Allegations Against DexCom - Defendants allegedly made false and misleading statements regarding unauthorized design changes to the G6 and G7 continuous glucose monitoring systems [2]. - The design changes reportedly rendered the G6 and G7 devices less reliable, posing a material health risk to users [2]. - DexCom is accused of overstating the enhancements and reliability of the G7 device, downplaying the severity of issues related to adulterated devices [2]. - The company allegedly faced increased regulatory scrutiny and potential legal, reputational, and financial harm due to these issues [2]. Group 2: Lead Plaintiff Process - Investors in DexCom can seek to be appointed as lead plaintiffs by December 26, 2025, or remain absent class members [3]. - The lead plaintiff represents the interests of all class members and selects counsel to direct the litigation [3]. - Participation as a lead plaintiff does not affect the ability to share in any recovery from the lawsuit [3]. Group 3: Contact Information - Kessler Topaz Meltzer & Check, LLP encourages affected DexCom investors to reach out for more information regarding the lawsuits [4].

Core Viewpoint - The Law Offices of Frank R. Cruz is encouraging shareholders of Avantor, Inc. (AVTR) to inquire about a potential securities fraud class action lawsuit [1] Group 1 - The law firm is actively seeking shareholders who may have been affected by the alleged securities fraud [1] - The announcement indicates a growing concern regarding the company's practices and potential legal implications [1] - Shareholders are urged to gather information and consider their options in light of the situation [1]

Core Viewpoint - The Law Offices of Frank R. Cruz is encouraging shareholders of Synopsys, Inc. (SNPS) to inquire about a potential securities fraud class action lawsuit [1] Group 1 - The law firm is actively seeking shareholders who may have been affected by the alleged securities fraud [1] - The announcement indicates a focus on protecting shareholder rights and addressing potential financial losses [1] - The firm is likely to investigate the circumstances surrounding the alleged fraud to determine the validity of claims [1]

Core Points - A class action lawsuit has been filed against V.F. Corporation (VFC) by Berger Montague on behalf of investors who purchased shares between October 30, 2023, and May 20, 2025 [1][2] - The lawsuit claims that VFC misled investors regarding the effectiveness of its turnaround plan, particularly for the Vans brand, failing to disclose necessary restructuring steps that were already in progress [3][4] - Following a report of a 20% decline in Vans revenue for Q4 fiscal 2025, VFC's stock price dropped over 15% in a single day, indicating significant investor concern [4] Company Overview - V.F. Corporation, headquartered in Denver, Colorado, is a global leader in branded lifestyle apparel, footwear, and accessories, owning well-known brands such as Vans, The North Face, Timberland, and JanSport [2] Financial Performance - In Q4 fiscal 2025, Vans revenue declined by 20%, worsening from an 8% decline in the previous quarter, attributed to undisclosed internal cost-cutting and restructuring actions [4] - VFC indicated that even without these restructuring measures, Vans would have experienced a high single-digit revenue decline, raising concerns about deeper issues within the brand [4]

Core Viewpoint - Law Offices of Frank R. Cruz is encouraging shareholders of aTyr Pharma Inc. to inquire about a potential securities fraud class action [1] Group 1 - The law firm is actively seeking shareholders of aTyr Pharma Inc. to participate in the inquiry regarding the alleged securities fraud [1] - The announcement indicates a growing concern among investors about the company's practices and potential legal implications [1]

Core Viewpoint - Law Offices of Frank R. Cruz is encouraging KBR, Inc. investors to inquire about a securities fraud class action, indicating potential legal issues surrounding the company [1] Group 1 - The law firm is actively seeking investors of KBR, Inc. to participate in the class action lawsuit [1] - The announcement suggests that there may be significant concerns regarding KBR's financial practices or disclosures [1] - This legal action could impact KBR's reputation and financial standing in the market [1]

Group 1 - The article discusses a securities fraud class action being encouraged by the Law Offices of Frank R. Cruz for investors of Fly-E Group, Inc. (FLYE) [1] - The law firm is reaching out to investors who may have been affected by the alleged fraud to inquire about their rights and potential claims [1] - The focus is on protecting the interests of investors and holding the company accountable for any misleading information [1]

Group 1 - The core issue involves an investigation by Berger Montague PC into potential securities law violations by Fiserv, Inc. following a class action lawsuit filed against the company and its executives [1][3] - The class action lawsuit pertains to investors who purchased Fiserv securities between July 24, 2024, and July 22, 2025, alleging that the company overstated its growth by not disclosing issues related to its Clover payment platform [3][2] - Investors have a deadline of September 22, 2025, to seek appointment as lead plaintiff representatives in the class action [2][4] Group 2 - Fiserv is recognized as a leading provider of financial services technology, including payment and processing systems utilized by institutions globally [2] - The lawsuit claims that Fiserv's executives misrepresented the company's performance by failing to reveal that the revenue growth of Clover was artificially inflated due to the forced transition of merchants from the legacy Payeezy platform [3]

Group 1 - RxSight, Inc. is under investigation for potential securities fraud claims following significant declines in sales and revenue [1][2] - The company reported a 37% drop in share price, closing at $7.95 per share after disclosing adoption challenges affecting LDD sales and LAL utilization [2] - Investors who acquired RxSight stock between November 7, 2024, and July 8, 2025, may seek lead plaintiff status in the ongoing litigation [3] Group 2 - RxSight specializes in medical technology, specifically developing light adjustable intraocular lenses (LAL) for cataract surgery [1] - The company's Light Delivery Device (LDD) is a key component of its RxSight system [1]

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased Iovance Biotherapeutics, Inc. securities between May 9, 2024, and May 8, 2025, alleging that the company misled investors regarding its business prospects [1][2]. Company Performance - Iovance Biotherapeutics reported a total product revenue of $49.3 million for Q1 2025, a significant decline from $73.7 million in the previous quarter [3]. - The company revised its full fiscal year 2025 total product revenue guidance from $450 million - $475 million to $250 million - $300 million, indicating a reduction of over 40% at the midpoint [3]. - The updated revenue forecast reflects challenges with the launch dynamics of Amtagvi and the growth trajectories of Authorized Treatment Centers (ATCs) [3]. Allegations and Issues - The lawsuit claims that Iovance failed to disclose several critical issues, including: 1. New ATCs faced longer timelines to begin treating patients with Amtagvi [2]. 2. Ineffectiveness of the sales team and ATCs in patient identification and selection, leading to higher patient drop-offs [2]. 3. These dynamics resulted in higher costs and lower revenue due to ATCs not keeping pace with manufactured products [2]. 4. Positive statements made by the company regarding its business and prospects were materially misleading [2]. Legal Proceedings - Shareholders interested in serving as lead plaintiffs in the class action must file their papers with the court by July 14, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].